{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '10.', 'STUDY TREATMENTS', '59', '10.1.', 'Treatments Administered', '59', '10.1.1.', 'Study Treatments', '59', '10.2.', 'Dose Schedules and Administration', '59', '10.2.1.', 'Labeling', '59', '10.2.2.', 'Dispensing Directions', '59', '10.2.3.', 'Dosing Information', '59', '10.2.3.1.', 'Dosing Sequence and Timing', '59', '10.2.3.2.', 'Selinexor', '59', '10.2.3.3.', 'Bortezomib', '60', '10.2.3.4.', 'Dexamethasone', '60', '10.2.4.', 'Dose Schedules for Evaluation', '60', '10.2.4.1.', 'SVd Arm', '60', '10.2.4.2.', 'Vd Arm', '60', '10.2.4.3.', 'SVdX Patients', '61', '10.2.4.4.', 'SdX Patients', '61', '10.2.5.', 'Selinexor Dose Escalation', '61', '10.2.6.', 'Duration of Treatment and Follow-up', '61', '10.3.', 'Supportive Care for All Patients', '61', '10.3.1.', 'Required 5-HT3 Antagonists', '61', '10.3.2.', 'Recommended Supportive Care', '62', '10.3.3.', 'Infection', '62', '10.3.4.', 'Glucocorticoid Side Effects', '62', '10.3.5.', 'Overdose', '62', '10.4.', 'Dose Modifications', '62', '10.4.1.', 'Selinexor Dose Reduction Guidelines', '63', '10.4.1.1.', 'Selinexor Dose Adjustment in the Setting of Infection', '67', '10.4.1.2.', 'Conditions Not Requiring Selinexor Dose Reduction', '67', '10.4.2.', 'Dose Modifications for Overlapping Toxicities', '68', '10.4.3.', 'Bortezomib Dose Modifications', '68', '10.4.4.', 'Dexamethasone Dose Modifications', '68', '10.5.', 'Missed or Vomited Doses', '68', 'Confidential', 'Page 6', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '10.5.1.', 'Missed Doses of Study Treatments (Selinexor, Bortezomib, and', 'Dexamethasone)', '68', '10.5.2.', 'Vomited Doses of Selinexor', '69', '10.6.', 'Sponsor-supplied Study Treatment Accountability', '69', '10.7.', 'Compliance', '69', '10.8.', 'Contraception Requirements and Concomitant Medications', '70', '10.8.1.', 'Contraception Requirements', '70', '10.8.2.', 'Non-study-related Concomitant Medication and Treatment', '70', '10.8.2.1.', 'Permitted Concomitant Medication', '71', '10.8.2.2.', 'Use of Blood Products', '71', '10.8.2.3.', 'Radiation Treatment', '71', '10.8.3.', 'Restrictions for Study Treatment', '71', '10.8.3.1.', 'Restrictions for Selinexor', '71', '10.8.3.2.', 'Restrictions for Bortezomib and Dexamethasone', '71', '10.8.4.', 'Prohibited Medications', '72', '11.', 'ASSESSMENTS', '73', '11.1.', 'Informed Consent', '73', '11.2.', 'Demographic and Baseline Characteristics Assessments', '73', '11.2.1.', 'Demographics', '73', '11.2.2.', 'Medical History', '73', '11.3.', 'Efficacy Assessments', '73', '11.3.1.', 'Multiple Myeloma Disease Assessments', '73', '11.3.1.1.', 'SPEP', '78', '11.3.1.2.', 'UPEP', '78', '11.3.1.3.', 'Quantitative Immunoglobulin Levels', '78', '11.3.1.4.', 'Serum FLC', '78', '11.3.1.5.', '82 microglobulin', '78', '11.3.1.6.', 'LDH', '78', '11.3.1.7.', 'Skeletal Survey', '78', '11.3.1.8.', 'Clinical Plasmacytoma Assessment', '79', '11.3.1.9.', 'Bone Marrow Aspirate', '79', '11.3.1.10. Bone Marrow Core (Trephine) Biopsy', '80', '11.4.', 'Pharmacokinetic and Pharmacodynamic Procedures', '80', 'Confidential', 'Page 7', 'Version 4.0']\n\n###\n\n", "completion": "END"}